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Pfficacy and Safety of Torcetrapib, a Novel
holesteryl Ester Transfer Protein Inhibitor,
n Individuals With Below-Average High-Density
ipoproteinCholesterol Levels on a Background of Atorvastatin
ames M. McKenney, PHARMD,* Michael H. Davidson, MD, FACC,† Charles L. Shear, DRPH,‡
ames H. Revkin, MD, FACC‡
ichmond, Virginia; Chicago, Illinois; and New London, Connecticut
OBJECTIVES This study sought to evaluate the efficacy and safety of torcetrapib in patients with low
high-density lipoprotein cholesterol (HDL-C) levels receiving background atorvastatin.
BACKGROUND Elevating HDL-C levels may reduce the residual cardiovascular risk that is observed in
patients treated with statin therapy. Torcetrapib (a cholesteryl ester transfer protein inhibitor)
increases HDL-C and decreases low-density lipoprotein cholesterol (LDL-C).
METHODS This was a multicenter, double-blind, randomized trial. Patients with below-average HDL-C (men
44mg/dl; women54mg/dl) whowere eligible for statin therapy according toNationalCholesterol
Education Program Adult Treatment Panel III guidelines or who had LDL-C 130 mg/dl at
screening entered an 8-week run-in period with atorvastatin 20 mg/day before randomization (n 
174) to torcetrapib 10, 30, 60, or 90mg/day or placebo for 8 weeks. Atorvastatin was continued during
treatment with torcetrapib.
RESULTS After 8 weeks, the percent change from baseline with torcetrapib (least-squares mean
difference from placebo) ranged from 8.3% to 40.2% for HDL-C (p 0.0001 for 30-mg and
higher doses) and from 0.6% to 18.9% for LDL-C (p  0.01 for 60-mg and 90-mg doses).
Particle size for both HDL and LDL increased with torcetrapib. The incidence of
all-causality and treatment-related adverse events was similar across placebo and torcetrapib
treatment groups with no evidence of a dose-related response. In some treatment groups,
small increases in systolic and diastolic blood pressures were noted.
CONCLUSIONS In statin-eligible patients, torcetrapib plus background atorvastatin resulted in substantial, dose-
dependent increases in HDL-C, accompanied by additional decreases in LDL-C beyond those seen
with atorvastatin alone. Torcetrapib plus atorvastatinwas generally well tolerated. (J AmCollCardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.0662006;48:1782–90) © 2006 by the American College of Cardiology Foundation
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fowering low-density lipoprotein cholesterol (LDL-C) lev-
ls is the primary focus of guidelines for the management of
ardiovascular disease (CVD) (1,2). Statins are the drugs of
See page 1791
hoice for decreasing LDL-C and have shown large reduc-
ions in cardiovascular events in CVD prevention trials (3).
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ccepted June 6, 2006.ecent data also confirm that aggressive versus more mod-
rate lipid-lowering therapy with statins is associated with
reater benefits (4–6).
Despite the impressive benefits of statins, it is apparent that
ven intensively treated patients retain a residual risk of cardiovas-
ular events. In the PROVE IT (Pravastatin or Atorvastatin
valuation and Infection Therapy) trial, in which patients with
cute coronary syndromes were randomized to either moderate
herapy with pravastatin 40 mg/day or intensive therapy with
torvastatin 80 mg/day, cardiovascular event rates were still
6.3% and 22.4%, respectively, after 2 years (6). Similarly, in
he TNT (Treating to New Targets) trial, which also evalu-
ted the benefits of intensive (atorvastatin 80 mg/day) versus
ore moderate (atorvastatin 10 mg/day) therapy, but in
atients with stable rather than unstable coronary heart
isease, a significant proportion of each treatment group
xperienced major vascular events after 5 years (8.7% vs.
0.9% with atorvastatin 80 mg and 10 mg, respectively) (5).
Reducing the residual cardiovascular risk in statin-treated
atients may be achieved by complementing statin therapy
ith strategies targeting other components of the dyslipi-
emic state. As shown by the ARBITER (Arterial Biology
or the Investigation of the Treatment Effects of Reducing
holesterol) 2 trial, one promising strategy may be to
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November 7, 2006:1782–90 Torcetrapib/Atorvastatin in Patients With Low HDLlevate high-density lipoprotein cholesterol (HDL-C) lev-
ls. In the ARBITER 2 trial, addition of extended-release
iacin to statin therapy increased HDL-C by 21% and
lowed the progression of atherosclerosis (as measured by
hange in carotid intima-media thickness) compared with
tatin therapy alone in patients with known coronary heart
isease and moderately low HDL-C levels (7).
One approach for elevating HDL-C is via the inhibition of
holesteryl ester transfer protein (CETP) (8). As described in
n accompanying article (see pages 1774–1781 in this issue of
he Journal), torcetrapib is a novel CETP inhibitor that
ubstantially elevates HDL-C, modestly decreases LDL-C,
nd increases lipid particle size. The phase 2 study reported
ere provides additional data on the efficacy and safety of
orcetrapib when administered on a background of atorvastatin
o patients with a low level of HDL-C.
ETHODS
tudy design. This was a multicenter study (23 centers).
fter screening, participants entered an 8-week run-in
eriod during which they received atorvastatin 20 mg/day.
he HDL-C levels were verified during this run-in period.
ligible participants were then randomized to 8 weeks of
Abbreviations and Acronyms
AE  adverse event
apo  apolipoprotein
CETP  cholesteryl ester transfer protein
CVD  cardiovascular disease
DBP  diastolic blood pressure
HDL-C  high-density lipoprotein cholesterol
LDL-C  low-density lipoprotein cholesterol
LS  least-squares
NMR  nuclear magnetic resonance
SBP  systolic blood pressure
ULN  upper limit of normal
VLDL-C  very low-density lipoprotein cholesterol
igure 1. Schematic representation of study design and numbers of patients. A
HDL-C) level 44 mg/dl for men and 54 mg/dl for women, and 2) be on
g/dl. A total of 69 patients were already receiving statin therapy at screenin
er group yielding 80% power to detect a 25% treatment difference in HDL-C, assu
error. LOCF  last observation carried forward (i.e., patients with baseline plusouble-blind treatment with either placebo or torcetrapib
0, 30, 60, or 90 mg once daily (Fig. 1). Atorvastatin
herapy was continued during double-blind treatment.
articipants. Adults ages 18 to 65 years with low HDL-C
evels (44 mg/dl for men and 54 mg/dl for women) (9)
ere enrolled. Patients were also required to be on statin
herapy or to have an LDL-C level 130 mg/dl. Exclusion
riteria included an LDL-C level of 190 mg/dl or
riglycerides 400 mg/dl, concomitant therapy with
nown lipid-altering effects on HDL-C (other than statins)
ithin 30 days of screening, and major and/or unstable
oncurrent illnesses.
The protocol was approved by the institutional review
oard or independent ethics committee at each site and was
onducted in compliance with the Declaration of Helsinki.
ipid assessments. The primary end point was the per-
ent change from baseline in HDL-C after 8 weeks.
bsolute change from baseline in HDL-C and percent
hange and absolute change from baseline in LDL-C,
riglycerides, and total cholesterol were secondary end
oints. Additional lipid analyses included apolipoprotein
oncentrations; HDL particle type; HDL, very low-
ensity lipoprotein (VLDL), and LDL subclass compo-
ition; phospholipid concentrations; and nuclear mag-
etic resonance (NMR) lipoprofile.
nalytical methods. Biochemical analyses were performed
y Medical Research Laboratories (Highland Heights,
entucky). Total cholesterol and net triglycerides were quan-
ified by a Centers for Disease Control and Prevention–
tandardized enzymatic assay in an automated chemistry
nalyzer. The HDL-C was measured by separating HDL
rom LDL and VLDL by heparin/MnCl2 chemical precip-
tation. The LDL-C and VLDL cholesterol (VLDL-C)
ere estimated using the Friedewald formula (10). If total
riglycerides were400 mg/dl, LDL-C and VLDL-C were
easured directly by -quantification using ultracentrifuga-
ion. Phospholipid was measured by an automated enzy-
ening, patients were required to: 1) have a high-density lipoprotein cholesterol
n therapy or have a low-density lipoprotein cholesterol (LDL-C) level 130
ple size was calculated based on earlier torcetrapib studies, with 25 patientst scre
stati
g. Sam
ming a common standard deviation of 30.5% and 2-sided t test with 5% type
1 post-baseline HDL-C measurement); R  randomization.
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Torcetrapib/Atorvastatin in Patients With Low HDL November 7, 2006:1782–90atic colorimetric method. The HDL subclasses (HDL2
nd HDL3) were separated by zonal ultracentrifugation.
polipoprotein (apo) A-I, A-II, and B-100 were analyzed
y an automated immunoturbidimetric procedure. Lipopro-
ein subclasses were determined using proton NMR by
iposciences (Raleigh, North Carolina) (11).
afety assessments. Safety assessments included a physical
xamination and measurement of vital signs, electrocardio-
rams, and standard laboratory safety tests. Adverse events
AEs) were recorded.
tatistical analyses. The primary statistical analysis for effi-
acy included all randomized participants who received at least
dose of study treatment with at least 1 pretreatment and
ost-treatment end point measurement using the last-
bservation-carried-forward approach. The analysis of the
rimary end point (HDL-C percent change from baseline at
eek 8) used analysis of covariance using a linear model that
ncluded a term for treatment group and baseline value as a
ontinuous covariate (SAS Proc Mixed using SAS version
.12; SAS Institute Inc., Cary, North Carolina). Study center
as not included as an independent variable. Least-squares
LS) means were computed, and pairwise treatment compar-
sons of torcetrapib dose group versus placebo (on a back-
round of atorvastatin) were assessed for statistical significance
t the p 0.05 level (2-sided) using a step-down procedure to
able 1. Baseline Patient Demographics and Lipid Parameters (A
Placebo
emographics
n 37
Men, n (%) 25 (68)
Mean age, yrs (SD) 50 (9)
Men 50 (10)
Women 52 (7)
Race or ethnicity, n (%)
White 28 (75)
Black 1 (3)
Asian 1 (3)
Hispanic 6 (16)
Other 1 (3)
ean BMI, kg/m2
Men 29.5
Women 28.9
ean SBP/DBP, mm Hg 118.5/77.7
ipid parameters
n 37
Mean HDL-C, mg/dl (SD)* 40 (6)
% 40 mg/dl 62
Mean LDL-C, mg/dl (SD)* 88 (20)
% 130 mg/dl 100
Mean TGs, mg/dl (SD)* 170 (75)
% 150 mg/dl 41
Mean TC, mg/dl (SD)* 162 (27)
% 200 mg/dl 95
Ratio of LDL-C to HDL-C (SD)* 2.3 (0.6)
Baseline values are the measurements taken at the end of the atorvastatin run-in pe
BMI  body mass index; DBP  diastolic blood pressure; HDL-C  high-dens
lood pressure; TC  total cholesterol; TGs  triglycerides.reserve the type 1 error across the multiple comparisons (12). g95% confidence interval, unadjusted for multiplicity, was
alculated for each pairwise comparison. Similar analyses were
erformed for secondary end points.
For lipid assessments, results are presented in figures as raw
eans for each time point. The percent changes in lipids at 8
eeks used for hypothesis testing are presented in tabular form.
For vital signs, each patient’s post-baseline observations
ere averaged and a change from baseline was calculated.
his measure was then analyzed in a manner analogous to
he efficacy parameters previously discussed (i.e., analysis of
ovariance using SAS Proc Mixed with a linear model.
ncluding a term for treatment group and baseline value as
continuous covariate). The LS means were calculated, and
5% confidence intervals were computed for the within-
reatment group change from baseline.
ESULTS
aseline demographics. Baseline demographic character-
stics and lipid profiles of the randomized participants (n 
74) were well balanced across treatment groups (Table 1).
ean HDL-C levels across treatment groups ranged from
9 to 42 mg/dl. Between 41% and 62% of the individuals in
ach group had HDL-C levels 40 mg/dl. Predictably,
bjects Received Background Atorvastatin 20 mg/day)
Torcetrapib (mg/day)
0 30 60 90
39 31 33
74) 31 (79) 25 (81) 23 (70)
9) 49 (9) 49 (8) 49 (8)
9) 49 (9) 48 (8) 48 (7)
11) 50 (9) 54 (6) 51 (11)
79) 34 (87) 22 (71) 22 (67)
3) 1 (3) 2 (6) 2 (6)
0) 0 (0) 0 (0) 0 (0)
18) 4 (10) 7 (23) 8 (24)
0) 0 (0) 0 (0) 1 (3)
.7 30.3 30 28.9
.6 33.5 29.5 27.9
/76.9 117.1/75.1 119.4/79.4 121.4/78.8
37 31 32
6) 39 (7) 40 (6) 42 (6)
59 58 41
22) 85 (17) 83 (19) 89 (17)
97 97 100
71) 163 (70) 165 (67) 151 (63)
51 45 66
25) 157 (22) 155 (19) 161 (24)
97 100 91
0.5) 2.2 (0.6) 2.1 (0.6) 2.2 (0.6)
oprotein cholesterol; LDL-C  low-density lipoprotein cholesterol; SBP  systolicll Su
1
34
25 (
49 (
49 (
49 (
27 (
1 (
0 (
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34
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November 7, 2006:1782–90 Torcetrapib/Atorvastatin in Patients With Low HDLatients in each group with LDL-C levels 130 mg/dl
anged from 94% to 100%.
fficacy—lipid parameters. Generally, the pattern of changes
n the levels ofHDL-C,LDL-C, and their respective apolipopro-
eins in this study of torcetrapib administered on a background
f atorvastatin 20 mg/day to patients with below-average
DL-C levels was similar to that observed in a study of
orcetrapib administered alone to an equivalent cohort of
atients (see accompanying article, pages 1774–1781 in this
ssue of the Journal ).
DL AND HDL-RELATED APOLIPOPROTEINS. Torcetrapib on
background of atorvastatin dose-dependently increasedHDL-C
able 2. Change in Standard Lipid Parameters (All Subjects Rec
Mean Values at Baseline and
Lipid Parameter Placebo 10
DL-C 40, 40 39, 4
DL-C 88, 91 84, 8
riglycerides 170, 165 176, 1
otal cholesterol 162, 164 158, 1
DL-C/HDL-C ratio 2.3, 2.3 2.1, 2
po B-100/apo A-I ratio 0.8, 0.8 0.8, 0
Percent Change From Baseline at Week 8 (LS Mean
Lipid Parameter 10
DL-C (95% CI) 8.3 (0.2, 16.9) 23.8
DL-C (95% CI) 0.6 (8.9, 10.1) 2
riglycerides (95% CI) 2.1 (13.1, 17.3) 7
otal cholesterol (95% CI) 3.0 (2.8, 8.8) 9
DL-C/HDL-C ratio (95% CI) 7.1 (18.5, 4.3) 15.8
po B-100/apo A-I ratio (95% CI) 4.2 (15.3, 6.9) 10
p  0.05. †p  0.01. ‡p  0.0001.
apo  apolipoprotein; CI  confidence interval; HDL-C  high-density lipopro
arried forward; LS  least-squares.Figure 2. Mean change in high-density lipoprotein cholesteroevels (Table 2, Fig. 2). Percent changes inHDL-C from baseline
o week 8 ranged from8.3% to40.2% with torcetrapib 10 to
0 mg/day (LS mean difference from placebo). Differences were
ignificant at doses of 30 mg and above (p  0.0001). In each
orcetrapib treatment group, increases in HDL-C levels were
ccompanied by increases in apo A-I and apo A-II levels
Table 3).
Ultracentrifugation/precipitation analysis indicated that
orcetrapib on a background of atorvastatin increased levels
f larger HDL particles (Table 3). The NMR spectroscopy
onfirmed these findings. At the 60-mg and 90-mg doses of
orcetrapib, large HDL (8.3 to 13 nm) increased from 14.9
Background Atorvastatin 20 mg/day)
k 8 (Baseline, Final mg/dl)
Torcetrapib (mg/day)
30 60 90
39, 49 40, 53 42, 60
85, 90 83, 74 89, 75
163, 175 165, 169 151, 141
157, 174 155, 160 161, 162
2.2, 1.9 2.1, 1.5 2.2, 1.4
0.8, 0.7 0.7, 0.7 0.8, 0.6
rences Relative to Placebo Using LOCF Approach)
Torcetrapib (mg/day)
0 60 90
.4, 32.2) 33.1‡ (24.3, 41.9) 40.2‡ (31.3, 49.1)
.6, 12.0) 15.7† (25.5, 6.0) 18.9† (28.5, 9.3)
.0, 22.8) 5.0 (10.6, 20.6) 12.3 (27.8, 3.2)
, 14.8) 1.3 (4.7, 7.2) 0.2 (6.1, 5.7)
6.9, 4.7) 31.8‡ (43.5, 20.1) 39.8‡ (51.4, 28.3)
1.0, 0.52) 13.5* (24.8, 2.2) 25.1‡ (36.3, 13.9)
olesterol; LDL-C  low-density lipoprotein cholesterol; LOCF  last observationeived
Wee
3
6
78
65
.0
.7
Diffe
3
‡ (15
.7 (6
.9 (7
.1 (3.4
† (2
.3 (2l (HDL-C) over the course of the study—all patients.
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Torcetrapib/Atorvastatin in Patients With Low HDL November 7, 2006:1782–90SD 6.0) to 27.9 mg/dl (SD 11.2), equivalent to a 94%
ncrease, and from 17.8 (SD  6.5) to 36.0 mg/dl
SD  16.1), equivalent to a 113% increase, respectively
p  0.0001 for both). At the same doses, mean HDL
article size also increased from 8.4 (0.3) to 8.8 nm
0.4) and from 8.5 (0.2) to 9.1 nm (0.5), respec-
ively (p  0.0001 for both).
PO B-RELATED LIPOPROTEINS. AtWeek 8, torcetrapib on a
ackground of atorvastatin produced moderate but significant
ecreases in LDL-C levels from baseline (LS mean difference
able 3. Change in Other Lipid Parameters (All Patients Receiv
Mean Values at Baseline and
Parameter Placebo
ipoproteins
Apo A-I 132.0, 127.4 1
Apo A-II 30.5, 29.7
Apo B-100 101.5, 99.2
Non–HDL-C 121.8, 123.7 1
ltracentrifugation/precipitation analysis
HDL-2 cholesterol 11.4, 12.0
HDL-3 cholesterol 28.7, 27.9
Percent Change From Baseline at Week 8 (LS Mean
Parameter 10
ipoproteins
Apo A-I (95% CI) 4.3 (2.3, 10.9)
Apo A-II (95% CI) 6.4* (0.8, 12.0)
Apo B-100 (95% CI) 0.1 (7.8, 7.7)
Non–HDL-C (95% CI) 0.8 (7.5, 9.1)
ltracentrifugation/precipitation analysis
HDL-2 cholesterol (95% CI) 10.1 (30.3, 50.5)
HDL-3 cholesterol (95% CI) 4.5 (4.1, 13.1)
p  0.05. †p  0.01. ‡p  0.0001.
Abbreviations as in Table 2.Figure 3. Mean change in low-density lipoprotein cholesterorom placebo) at both the 60-mg (15.7%; p 0.01) and 90-mg
18.9%; p  0.01) doses (Table 2, Fig. 3). These significant
ffects on LDL-C lowering were maintained regardless of
hether baseline triglyceride levels were low or high; this was not
he case in the companion study of patients receiving torcetrapib
lone (Table 4). The Apo B-100 levels were decreased in the
orcetrapib 60-mg (6.3%) and 90-mg (14.9%; p  0.01)
reatment groups (Table 3).
The NMR analysis showed a trend toward reduction in
he concentration of the small LDL-C subclass. At the
ckground Atorvastatin 20 mg/day)
k 8 (Baseline, Final mg/dl)
Torcetrapib (mg/day)
0 30 60 90
134.7 131.4, 147.0 130.5, 141.3 136.2, 149.2
32.1 30.1, 33.1 31.3, 33.8 31.4, 33.7
97.6 98.5, 101.2 97.2, 90.2 101.5, 84.6
121.5 117.5, 124.7 115.7, 107.2 119.3, 102.8
14.1 11.6, 15.5 10.9, 18.0 12.8, 23.6
28.7 27.6, 33.0 28.6, 34.9 29.2, 36.1
rences Relative to Placebo Using LOCF Approach)
Torcetrapib (mg/day)
30 60 90
(8.8, 21.7) 11.6† (4.9, 18.3) 14.8‡ (8.1, 21.5)
(6.7, 17.5) 11.3† (5.6, 16.9) 11.0† (5.4, 16.7)
(3.9, 11.2) 6.3 (14.2, 1.6) 14.9† (22.7, 7.0)
(4.2, 12.0) 9.8* (18.3, 1.3) 16.0† (24.4, 7.6)
(13.0, 66.0) 74.2† (33.1, 115.3) 74.1† (32.2, 115.0)
(11.6, 28.4) 26.3‡ (17.6, 35.0) 27.7‡ (19.1, 36.4)ed Ba
Wee
1
34.3,
31.1,
99.5,
18.6,
11.5,
27.8,
Diffe
15.2†
12.1†
3.7
3.9
26.5
20.0‡l (LDL-C) over the course of the study—all patients.
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November 7, 2006:1782–90 Torcetrapib/Atorvastatin in Patients With Low HDL0-mg and 90-mg doses of torcetrapib, small LDL (18.3 to
9.7 nm) decreased from 26.0 (SD  34.3) to 13.3 mg/dl
SD  14.8) and from 25.1 (SD  31.9) to 13.9 mg/dl
SD  31.5), respectively (p  0.13, not significant for
oth). The NMR spectroscopy showed that LDL particle
ize was increased dose dependently. Torcetrapib 60 mg and
0 mg increased mean LDL particle size from 20.4 (0.7)
o 21.0 nm (0.5) and from 20.5 (0.6) to 21.2 nm (0.7),
espectively (p  0.0001 for both).
There was a 24.4% decrease from baseline in VLDL-C at
eek 8 with torcetrapib 90 mg (p  0.0128). The VLDL
riglyceride levels did not show any consistent dose-related pattern.
Non-HDL cholesterol levels were significantly decreased
rom baseline in the torcetrapib 60-mg and 90-mg groups (p
0.05 and p  0.01, respectively) (Table 3).
able 4. Effect of Baseline Triglyceride (TG) Levels on Mean Pe
lacebo at Week 8, LOCF)
Companion Study 10 30
TG 150 mg/dl 0.8 (9.5, 11.1) 2.9 (14
n 13 10
TG 150 mg/dl 1.5 (14.1, 11.0) 6.8 (5.6
n 19 20
Torcetrapib (m
Current Study 10 30
G 150 mg/dl 8.1 (24.5, 8.2) 3.8 (18.9
n 14 19
G 150 mg/dl 7.3 (3.8, 18.4) 9.7 (1.5,
n 20 18
p  0.05; †p  0.01; ‡p  0.0001.
Abbreviations as in Table 2.igure 4. Change in LDL-C/HDL-C ratio over the course of the study—a
ow-density lipoprotein cholesterol.IPID RATIOS, TOTAL CHOLESTEROL, AND TRIGLYCERIDES.
tWeek 8, torcetrapib on a background of atorvastatin produced
ose-related decreases in the LDL-C/HDL-C ratio of up to
40% (p 0.01 for doses of 30 mg and above), consistent with
he observed increases inHDL-C levels and decreases in LDL-C
evels (Table 2, Fig. 4). The final LDL-C/HDL-C ratio in the
orcetrapib 60-mg and 90-mg groups was 1.5. Similarly, at
eek 8, there were dose-related decreases in the apo B-100/apo
-I ratio (Table 2). No consistent dose-dependent effects on the
evels of total cholesterol or triglycerides were observed (Table 2).
afety and tolerability. Administering torcetrapib on a
ackground of atorvastatin did not seem to alter the safety
rofile of torcetrapib from that observed in a study of
orcetrapib monotherapy (see accompanying article, pages
774–1781 in this issue of the Journal ).
t Change (95% CI) in LDL-C (LS Mean Difference Relative to
Torcetrapib (mg/day)
60 90
) 22.2 (32.7, 11.6)‡ 32.9 (44.3, 21.4)‡
12 9
) 0.1 (12.0, 12.2) 10.3 (22.2, 1.5)
22 24
) Plus Background Atorvastatin 20 mg/day
60 90
) 17.9 (34.3, 1.6)* 20.0 (34.9, 5.2)†
14 21
13.6 (25.1, 2.2)* 17.0 (30.1, 3.8)*
17 11rcen
.0, 8.3
, 19.2
g/day
, 11.4
20.9)ll patients. HDL-C  high-density lipoprotein cholesterol; LDL-C 
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Torcetrapib/Atorvastatin in Patients With Low HDL November 7, 2006:1782–90Across the investigated dose range, torcetrapib was
enerally well tolerated. Treatment-related discontinua-
ions from the study were rare, consisting of 4 patients
eceiving torcetrapib 30 mg and 1 patient receiving
orcetrapib 90 mg (Table 5). Two patients had a tempo-
ary discontinuation of treatment. The AEs leading to
reatment-related discontinuations included lightheaded-
ess, eye pain, headache, fever, diarrhea, night sweats,
nd intermittent epigastric pain.
The incidence of all-causality and treatment-related AEs
as similar across placebo and torcetrapib groups with no
vidence of a dose-related response (Table 5). Flatulence and
ausea were the most frequently reported treatment-related
Es. Most AEs were mild or moderate in nature. There were
o treatment-related serious AEs in this study.
Laboratory test abnormalities showed no dose-related
rends. Only 1 patient in the torcetrapib 90-mg group showed
levated liver transaminase levels (AST/ALT 3 the upper
imit of normal [ULN]), and that patient had a baseline level
3 ULN before randomization. One patient on torcetrapib
0 mg had a creatine kinase level 10  ULN (Table 5),
hich was considered a result of exercise. Nomuscle symptoms
ere reported.
Changes from baseline in systolic and diastolic blood pres-
ure (SBP and DBP) at follow-up visits were highly variable in
oth placebo- and torcetrapib-treated patients, with no appar-
nt dose-dependent response (Fig. 5). Mean SBP changes over
he course of the study ranged from0.2 mmHg (torcetrapib
0-mg group) to 2.2 mm Hg (torcetrapib 60-mg group), with
nly the change in the 60-mg group achieving statistical
ignificance (Table 6). Mean DBP changes ranged from0.8
m Hg (placebo group) to 1.1 mm Hg (torcetrapib 90-mg
roup), with no significant change in any group (Table 6).
Of the patients receiving torcetrapib on a background of
torvastatin, 2.9% (4 of 137) showed significant elevations in
lood pressure defined as: 1) SBP15 mm Hg or DBP 10
m Hg from baseline at 3 consecutive visits, or 2) SBP
able 5. Summary of Safety—Number of Patients (%) (All Patie
(
reatment-related withdrawals
ubjects with AEs
All-causality
Treatment-related
erious AEs
All-causality
Treatment-related
(
linical laboratory tests
ALT/AST 3  ULN (with or without abnormal baseline†)
CK 10  ULN
One patient in the 30-mg group and the patient in the 90-mg group only temp
easurements taken at the end of the atorvastatin run-in period.
AE  adverse event; ALT  alanine aminotransferase; AST  aspartate aminot180 mm Hg with a 20 mm Hg change from baseline or
F
bBP 105 mm Hg with a 15 mm Hg change from
aseline at a single visit. No patient was permanently
iscontinued from the study because of elevated blood
ressure.
ISCUSSION
n an accompanying article (see pages 1774–1781 in this
ssue of the Journal ), we showed that torcetrapib produces a
eceived Background Atorvastatin 20 mg/day)
bo
7)
Torcetrapib (mg/day)
10
(n  34)
30
(n  39)
60
(n  31)
90
(n  33)
) 0 (0) 4 (10)* 0 (0) 1 (3)*
5) 13 (38) 24 (62) 12 (39) 20 (61)
9) 4 (12) 13 (33) 4 (13) 8 (24)
) 0 (0) 0 (0) 0 (0) 0 (0)
) 0 (0) 0 (0) 0 (0) 0 (0)
7) (n  34) (n  37) (n  31) (n  33)
) 0 (0) 0 (0) 0 (0) 1 (3)
) 0 (0) 0 (0) 0 (0) 1 (3)
discontinued from treatment and completed the study. †Baseline values are the
rase; CK  creatine kinase; ULN  upper limit of normal.nts R
Place
n  3
0 (0
24 (6
7 (1
1 (3
0 (0
n  3
0 (0
0 (0
orarilyigure 5. Least-squares mean change in systolic (A) and diastolic (B)
lood pressure over the course of the study.
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November 7, 2006:1782–90 Torcetrapib/Atorvastatin in Patients With Low HDLange of beneficial effects on lipoproteins when adminis-
ered to patients with low levels of HDL-C. The data that
e present here from an equivalent group of patients who
ere also receiving atorvastatin 20 mg show a similar
attern of beneficial lipoprotein changes. Specifically, there
ere substantial dose-dependent increases in HDL-C of up
o 40.2% with the 90-mg dose, modest decreases in LDL-C
ith both the 60-mg (15.7%) and 90-mg (18.9%) doses,
ncreases in HDL and LDL particle size with all doses, and
reduction in the LDL-C/HDL-C ratio to 1.5 with the
0-mg and 90-mg doses. Torcetrapib plus background
torvastatin also produced a similar pattern of changes in
po A-I, A-II, and B-100 as with torcetrapib alone. Of
ote, particularly with respect to LDL-C, changes in
ipoprotein levels in this study are additive to those achieved
ith atorvastatin monotherapy.
Interestingly, there was no apparent loss of LDL-C
eduction in this study when baseline triglycerides were
igh, unlike that observed in the companion study of
orcetrapib monotherapy. As discussed in the accompanying
rticle, one possible explanation for this observation may be
s follows. In the metabolic setting of high triglycerides, the
ombination of compositional changes in VLDL-1 and
ETP inhibition may lead to accelerated conversion of
LDL to LDL via lipoprotein lipase, which may nullify the
ffect of torcetrapib on LDL-C levels. However, with statin
herapy, up-regulation of LDL receptors may help to reduce
ccumulation of LDL-C, thereby ensuring that the effect of
orcetrapib in patients with hypertriglyceridemia is more
onsistent with that observed in patients who are nor-
otriglyceridemic. These findings suggest that an apparent
imitation of CETP inhibitor monotherapy is overcome by
oncomitant statin therapy.
To date, the only other data pertaining to the addition of
CETP inhibitor to statin therapy comes from a study
ublished by Kuivenhoven et al. (13). In this study, 4 weeks
f treatment with JTT-705 600 mg in patients receiving
ackground pravastatin 40 mg resulted in a 30% decrease in
ETP activity, a 28% increase in HDL-C, and a 5%
ecrease in LDL-C.
Regarding safety, this study shows that torcetrapib is well
olerated when administered with atorvastatin. Discontinu-
tions from treatment were rare, and there were no dose-
able 6. Longitudinal Analysis of Changes in Blood Pressure: Av
atients, Observed Cases; All Patients Received Background Ato
Placebo
(n  37)
10
(n 
ystolic blood pressure
Least-squares mean change 0.39 0.20
95% confidence interval 1.29–2.07 1.91–
iastolic blood pressure
Least-squares mean change 0.84 0.28
95% confidence interval 2.00–0.32 0.90–elated trends in the incidences of AEs. Furthermore, torcetrapib with atorvastatin had no additional impact on
he slight increases in blood pressure that were observed in
he study of torcetrapib alone (see accompanying article,
ages 1774–1781 in this issue of the Journal ).
There is overwhelming evidence showing that lowering
DL-C with statins is associated with significant cardio-
ascular benefits (3), and current guidelines for CVD
revention maintain a focus on LDL-C as the primary risk
actor for modification (1,2). Indeed, the National Choles-
erol Education Program Adult Treatment Panel recently
ublished an update to their latest guidelines, in which
ptional therapeutic LDL-C goals of 70 mg/dl for very
igh-risk patients and 100 mg/dl for high-risk patients
ere suggested. Yet, given that there is substantial potential
or further risk reduction in statin-treated patients, there is
clear need for more comprehensive lipid management
argeting other elements of an atherogenic lipid profile. The
esults from this study show that by combining LDL- and
DL-targeted therapies, statin-eligible patients can achieve
lipid profile consistent with even lower cardiovascular risk.
omparing the results from this study with those from the
ompanion study of torcetrapib monotherapy, it is evident
hat 3-hydroxyl-3-methylglutaryl coenzyme A reductase
nhibition with atorvastatin and CETP inhibition with
orcetrapib have complementary actions, resulting in more
obust LDL-C lowering and LDL-C/HDL-C ratios ap-
roaching 1.0. Ultimately, large-scale, randomized clinical
rials are required to determine whether the addition of
orcetrapib to atorvastatin will prove to have a greater
mpact on atherosclerosis than atorvastatin alone. Several
uch studies are underway, including vascular imaging
tudies using ultrasound to measure carotid artery intima-
edia thickness and coronary atheroma volume (14–16).
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e of All Follow-Up Measures Over the Course of the Study (All
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Torcetrapib (mg/day)
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